RNN Should Run Again Today Print E-mail
By M.E.Garza   
Tuesday, 20 April 2010 08:38

After holding up very well against yet another ill-researched and most-likely short sponsored tabloid report, shares of Rexahn Pharmaceuticals (AMEX: RNN) are looking to run again. Some of the weak hands were shaken by the ploy, as usual, but one simple fact remains; the drug candidate, Serdaxin, is attracting possible buyers and partners who want the drug based on the results it is producing.

As the company revealed last week, at least six big pharmas want the drug and are exploring options in which to partner with the company.

As I reported earlier, the millions of naked shorts are starting to buy back into RNN. In addtion, there are several milestone payments and a forward looking news item next month that will continue to push the stock price higher.  In the opinion of many of us who follow the company, RNN is a $15 stock waiting to happen.

The company has stated that they have been receiving warrant exercise money and that they now have more than $10 million in cash. Keep in mind that they are set to receive $3.5 million from Teva in June in a further private placement at 20% above the stock's market price. This is in addition to the $4 million in milestone payments that they'll get from Teva by year end.

Don't forget, also, that next month the company will have some important Zoraxel data to present and they believe they will make a deal with one of the six interested major pharmas for Serdaxin. As a matter of fact, sources anticipate that partnership for Serdaxin by year's end is imminent.

If given the choice between choosing who is telling the truth about whether the science and trials about the drug are real or not, I'll go with the CEO of the company (who, by the way, headed two departments at the FDA) instead of a tabloid reporter. A so called reporter, who, by the way, is currently being sued by another company for,once again, misrepresenting the facts.

Don't listen to the dips, buy on them.


Disclosure: Long RNN

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus